Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on May 23, 2025
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
GlobeNewswire
·
May 23, 2025
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, …
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire
·
May 23, 2025
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that …
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
GlobeNewswire
·
May 23, 2025
Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, …
Boundless Bio Announces Portfolio Prioritization and Runway Extension
GlobeNewswire
·
May 23, 2025
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical …
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
GlobeNewswire
·
May 23, 2025
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. As previously reported in October 2024, …
Cross Medical Group Introduces HydraFacial Treatments for Advanced Skin Rejuvenation
GlobeNewswire
·
May 23, 2025
PHILADELPHIA and VILLANOVA, Pa., May 23, 2025 (GLOBE NEWSWIRE) -- Cross Medical Group is pleased to announce that HydraFacial treatments are now available at the practice. A HydraFacial at their Philadelphia and Villanova offices, which is sometimes …
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire
·
May 23, 2025
FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort Demonstrated tolerability …
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
GlobeNewswire
·
May 23, 2025
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the …
Mind Body Peak Performance Rebrands to ‘High Performance Longevity’ Podcast, Integrating Biohacking with Ancestral Wisdom
GlobeNewswire
·
May 23, 2025
Austin, TX, May 23, 2025 (GLOBE NEWSWIRE) -- Outliyr, a performance health brand known for combining modern biohacking with ancestral wisdom, has rebranded its podcast—formerly Mind Body Peak Performance—as High Performance Longevity to reflect a deeper …
Doug Ruch Brings His 50-State Volunteer Mission to Project C.U.R.E. Chicago
GlobeNewswire
·
May 23, 2025
CHICAGO, IL, May 23, 2025 (GLOBE NEWSWIRE) -- CHICAGO, IL — May 23, 2025 — Project C.U.R.E. is proud to welcome Doug Ruch to its Chicago distribution center on Friday, May 23, as part of his mission to volunteer in all 50 states. Diagnosed with terminal …
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
GlobeNewswire
·
May 23, 2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix …
Tilray Medical bringt die bekannte kanadische Cannabismarke Good Supply nach Deutschland
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Deutschland, May 23, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und ein weltweit führendes Unternehmen im Bereich des medizinischen Cannabis, das die …
Tilray Medical introduit Good Supply, la marque emblématique de cannabis canadienne, en Allemagne
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Allemagne, 23 mai 2025 (GLOBE NEWSWIRE) -- Tilray Medical (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux patients et aux professionnels de santé de …
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing …
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 23, 2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 23, 2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will take place during the “Developmental …
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
·
May 23, 2025
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP …
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
GlobeNewswire
·
May 23, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on …
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
May 23, 2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, …
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies …